StockData
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc. (EBS) stock

EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3074% below fair value
$5.50−0.11 (-1.96%)

Close on Nov 18, 2026Market cap $282.00MP/E –Yield –

Emergent BioSolutions free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Emergent BioSolutions's free cash flow for the twelve months ending Sep 30, 2026 was $188.40M, up 13357.1% year over year. For fiscal 2025 it was $156.80M, up 338.0% from the year before. The highest annual figure on record is $395.00M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$156.80M+338.0%
FY2024Dec 31, 2024$35.80M–
FY2023Dec 31, 2023-$257.90M–
FY2022Dec 31, 2022-$149.90M-256.0%
FY2021Dec 31, 2021$96.10M-75.7%
FY2020Dec 31, 2020$395.00M+290.7%
FY2019Dec 31, 2019$101.10M–
FY2018Dec 31, 2018-$30.30M-119.8%
FY2017Dec 31, 2017$153.30M–
FY2016Dec 31, 2016-$21.60M–
FY2015Dec 31, 2015-$2.30M-102.8%
FY2014Dec 31, 2014$81.65M+48.6%
FY2013Dec 31, 2013$54.95M–
FY2012Dec 31, 2012-$14.20M–
FY2011Dec 31, 2011-$41.84M-155.1%
FY2010Dec 31, 2010$75.92M–
FY2009Dec 31, 2009-$3.42M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$96.80M–
Q2 FY2026Jun 30, 2026$54.00M-47.8%
Q1 FY2026Mar 31, 2026-$36.20M–
Q4 FY2025Dec 31, 2025$73.80M–
Q3 FY2025Sep 30, 2025-$5.70M-103.9%
Q2 FY2025Jun 30, 2025$103.50M+141.3%
Q1 FY2025Mar 31, 2025-$14.80M–
Q4 FY2024Dec 31, 2024-$81.60M-494.2%
Q3 FY2024Sep 30, 2024$147.90M+212.0%
Q2 FY2024Jun 30, 2024$42.90M–
Q1 FY2024Mar 31, 2024-$73.40M–
Q4 FY2023Dec 31, 2023$20.70M-70.1%
Q3 FY2023Sep 30, 2023$47.40M–
Q2 FY2023Jun 30, 2023-$126.90M–
Q1 FY2023Mar 31, 2023-$199.10M–
Q4 FY2022Dec 31, 2022$69.20M-75.5%
Q3 FY2022Sep 30, 2022-$101.90M–
Q2 FY2022Jun 30, 2022-$47.70M–
Q1 FY2022Mar 31, 2022-$69.50M–
Q4 FY2021Dec 31, 2021$282.30M+35.0%
Q3 FY2021Sep 30, 2021-$38.50M-164.7%
Q2 FY2021Jun 30, 2021-$96.70M-204.2%
Q1 FY2021Mar 31, 2021-$51.00M-251.8%
Q4 FY2020Dec 31, 2020$209.10M+143.1%
Q3 FY2020Sep 30, 2020$59.50M–
Q2 FY2020Jun 30, 2020$92.80M–
Q1 FY2020Mar 31, 2020$33.60M-59.7%
Q4 FY2019Dec 31, 2019$86.00M–
Q3 FY2019Sep 30, 2019-$18.40M-112.4%
Q2 FY2019Jun 30, 2019-$49.90M-337.6%
Q1 FY2019Mar 31, 2019$83.40M–
Q4 FY2018Dec 31, 2018-$186.60M-386.8%
Q3 FY2018Sep 30, 2018$147.90M+567.3%
Q2 FY2018Jun 30, 2018$21.00M-53.0%
Q1 FY2018Mar 31, 2018-$12.60M-159.0%
Q4 FY2017Dec 31, 2017$65.07M–
Q3 FY2017Sep 30, 2017$22.17M–
Q2 FY2017Jun 30, 2017$44.70M–
Q1 FY2017Mar 31, 2017$21.37M–
Q4 FY2016Dec 31, 2016-$32.61M–

More Emergent BioSolutions figures

See a number that looks wrong?